Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group.
Adolescent
Biological Products
/ therapeutic use
COVID-19
/ epidemiology
Child
Colitis, Ulcerative
/ diagnosis
Crohn Disease
/ diagnosis
Disease Management
Endoscopy, Gastrointestinal
/ trends
Female
Gastrointestinal Agents
/ therapeutic use
Hospitalization
/ trends
Humans
Immunosuppressive Agents
/ therapeutic use
Inflammatory Bowel Diseases
/ diagnosis
Italy
/ epidemiology
Male
Recurrence
SARS-CoV-2
Telemedicine
/ trends
COVID-19
Inflammatory Bowel Disease
Paediatrics
immunosuppression
lockdown
telemedicine
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
13
10
2020
revised:
12
12
2020
accepted:
15
12
2020
pubmed:
4
1
2021
medline:
12
3
2021
entrez:
3
1
2021
Statut:
ppublish
Résumé
IBD management has been significantly affected during the COVID-19 lockdown with potential clinical issues. The aim of this study was to analyse the impact of COVID-19 pandemic on the Italian paediatric IBD cohort. This was a multicentre, retrospective, cohort investigation including 21 different Italian IBD referral centres. An electronic data collection was performed among the participating centres including: clinical characteristics of IBD patients, number of COVID-19 cases and clinical outcomes, disease management during the lockdown and the previous 9 weeks. 2291 children affected by IBD were enrolled. We experienced a significant reduction of the hospital admissions [604/2291 (26.3%) vs 1281/2291 (55.9%); p < 0.001]. More specifically, we observed a reduction of hospitalizations for new diagnosis (from n = 44 to n = 27) and endoscopic re-evaluations (from n = 46 to n = 8). Hospitalization for relapses and surgical procedures remained substantially unchanged. Biologic infusions did not significantly vary [393/2291 (17.1%) vs 368/2291 (16%); p = 0.3]. Telemedicine services for children with IBD were activated in 52.3% of the centres. In 42/2291(1.8%) children immunosuppressive therapies were adapted due to the concurrent COVID-19 pandemic. Due to the several limitations of the lockdown, cares for children with IBD have been kept to minimal standards, giving priorities to the urgencies and to biologics' infusions and implementing telemedicine services.
Sections du résumé
BACKGROUND
IBD management has been significantly affected during the COVID-19 lockdown with potential clinical issues.
AIMS
The aim of this study was to analyse the impact of COVID-19 pandemic on the Italian paediatric IBD cohort.
METHODS
This was a multicentre, retrospective, cohort investigation including 21 different Italian IBD referral centres. An electronic data collection was performed among the participating centres including: clinical characteristics of IBD patients, number of COVID-19 cases and clinical outcomes, disease management during the lockdown and the previous 9 weeks.
RESULTS
2291 children affected by IBD were enrolled. We experienced a significant reduction of the hospital admissions [604/2291 (26.3%) vs 1281/2291 (55.9%); p < 0.001]. More specifically, we observed a reduction of hospitalizations for new diagnosis (from n = 44 to n = 27) and endoscopic re-evaluations (from n = 46 to n = 8). Hospitalization for relapses and surgical procedures remained substantially unchanged. Biologic infusions did not significantly vary [393/2291 (17.1%) vs 368/2291 (16%); p = 0.3]. Telemedicine services for children with IBD were activated in 52.3% of the centres. In 42/2291(1.8%) children immunosuppressive therapies were adapted due to the concurrent COVID-19 pandemic.
CONCLUSION
Due to the several limitations of the lockdown, cares for children with IBD have been kept to minimal standards, giving priorities to the urgencies and to biologics' infusions and implementing telemedicine services.
Identifiants
pubmed: 33388247
pii: S1590-8658(20)31090-2
doi: 10.1016/j.dld.2020.12.011
pmc: PMC7832380
pii:
doi:
Substances chimiques
Biological Products
0
Gastrointestinal Agents
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
283-288Informations de copyright
Copyright © 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have no conflict of interests to declare with regards to this manuscript.
Références
Nat Rev Gastroenterol Hepatol. 2020 Aug;17(8):441-443
pubmed: 32483356
Gastroenterology. 2020 Jul;159(1):6-13.e6
pubmed: 32272113
Gastroenterology. 2020 Jul;159(1):14-19.e3
pubmed: 32360567
Gut. 2020 Jun;69(6):984-990
pubmed: 32303607
Am J Gastroenterol. 2019 Mar;114(3):472-482
pubmed: 30410041
Gastroenterology. 2020 Aug;159(2):481-491.e3
pubmed: 32425234
Gastroenterology. 2020 Jul;159(1):350-357
pubmed: 32283100
Gastroenterology. 2020 Jul;159(1):371-372
pubmed: 32247695
J Pediatr Gastroenterol Nutr. 2020 Jun;70(6):e140
pubmed: 32443060
Nat Rev Gastroenterol Hepatol. 2020 May;17(5):253-255
pubmed: 32214232
Inflamm Bowel Dis. 2020 Aug 20;26(9):1407-1414
pubmed: 31689349
J Pediatr Gastroenterol Nutr. 2020 Jun;70(6):734-740
pubmed: 32443021
Gastroenterology. 2020 Dec;159(6):2229-2231.e2
pubmed: 32860790
Dig Liver Dis. 2021 Feb;53(2):183-189
pubmed: 33132063
N Engl J Med. 2020 May 14;382(20):1873-1875
pubmed: 32187459
Dig Liver Dis. 2020 May;52(5):593-594
pubmed: 32276846
Inflamm Bowel Dis. 2021 May 17;27(6):836-847
pubmed: 32793973
Gut. 2010 Dec;59(12):1652-61
pubmed: 21071584
Arch Dis Child. 2020 Dec;105(12):1186-1191
pubmed: 32732316
Euro Surveill. 2020 May;25(18):
pubmed: 32400362
J Pediatr Gastroenterol Nutr. 2012 Jun;54(6):830-7
pubmed: 22584748
J Crohns Colitis. 2020 Sep 16;14(9):1334-1336
pubmed: 32215548
Lancet Child Adolesc Health. 2020 May;4(5):e10-e11
pubmed: 32278365
Inflamm Bowel Dis. 2020 Aug 20;26(9):e95-e96
pubmed: 32440675
Inflamm Bowel Dis. 2020 May 12;26(6):793-796
pubmed: 32314792
J Pediatr Gastroenterol Nutr. 2020 Jun;70(6):727-733
pubmed: 32443020
Inflamm Bowel Dis. 2015 Feb;21(2):392-9
pubmed: 25437818
JAMA Pediatr. 2020 Sep 01;174(9):882-889
pubmed: 32320004